Cargando…
Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria
Cerebral malaria (CM) is the most severe neurological complication of malaria caused by Plasmodium falciparum infection. The available antimalarial drugs are effective at clearing the parasite, but the mortality rate remains as high as 20% of CM cases. At the vascular level, CM is characterized by e...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229727/ https://www.ncbi.nlm.nih.gov/pubmed/35745497 http://dx.doi.org/10.3390/pathogens11060643 |
_version_ | 1784734823546355712 |
---|---|
author | Mota, Sabrina Bensalel, Johanna Park, Do Hee Gonzalez, Sandra Rodriguez, Ana Gallego-Delgado, Julio |
author_facet | Mota, Sabrina Bensalel, Johanna Park, Do Hee Gonzalez, Sandra Rodriguez, Ana Gallego-Delgado, Julio |
author_sort | Mota, Sabrina |
collection | PubMed |
description | Cerebral malaria (CM) is the most severe neurological complication of malaria caused by Plasmodium falciparum infection. The available antimalarial drugs are effective at clearing the parasite, but the mortality rate remains as high as 20% of CM cases. At the vascular level, CM is characterized by endothelial activation and dysfunction. Several biomarkers of endothelial activation have been associated with CM severity and mortality, making the brain vascular endothelium a potential target for adjunctive therapies. Statins and Angiotensin II Receptor Blockers (ARBs) are drugs used to treat hypercholesterolemia and hypertension, respectively, that have shown endothelial protective activity in other diseases. Here, we used a combination of a statin (atorvastatin) and an ARB (irbesartan) as adjunctive therapy to conventional antimalarial drugs in a mouse experimental model of CM. We observed that administration of atorvastatin–irbesartan combination decreased the levels of biomarkers of endothelial activation, such as the von Willebrand factor and angiopoietin-1. After mice developed neurological signs of CM, treatment with the combination plus conventional antimalarial drugs increased survival rates of animals 3–4 times compared to treatment with antimalarial drugs alone, with animals presenting lower numbers and smaller hemorrhages in the brain. Taken together, our results support the hypothesis that inhibiting endothelial activation would greatly reduce the CM-associated pathology and mortality. |
format | Online Article Text |
id | pubmed-9229727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92297272022-06-25 Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria Mota, Sabrina Bensalel, Johanna Park, Do Hee Gonzalez, Sandra Rodriguez, Ana Gallego-Delgado, Julio Pathogens Article Cerebral malaria (CM) is the most severe neurological complication of malaria caused by Plasmodium falciparum infection. The available antimalarial drugs are effective at clearing the parasite, but the mortality rate remains as high as 20% of CM cases. At the vascular level, CM is characterized by endothelial activation and dysfunction. Several biomarkers of endothelial activation have been associated with CM severity and mortality, making the brain vascular endothelium a potential target for adjunctive therapies. Statins and Angiotensin II Receptor Blockers (ARBs) are drugs used to treat hypercholesterolemia and hypertension, respectively, that have shown endothelial protective activity in other diseases. Here, we used a combination of a statin (atorvastatin) and an ARB (irbesartan) as adjunctive therapy to conventional antimalarial drugs in a mouse experimental model of CM. We observed that administration of atorvastatin–irbesartan combination decreased the levels of biomarkers of endothelial activation, such as the von Willebrand factor and angiopoietin-1. After mice developed neurological signs of CM, treatment with the combination plus conventional antimalarial drugs increased survival rates of animals 3–4 times compared to treatment with antimalarial drugs alone, with animals presenting lower numbers and smaller hemorrhages in the brain. Taken together, our results support the hypothesis that inhibiting endothelial activation would greatly reduce the CM-associated pathology and mortality. MDPI 2022-06-02 /pmc/articles/PMC9229727/ /pubmed/35745497 http://dx.doi.org/10.3390/pathogens11060643 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mota, Sabrina Bensalel, Johanna Park, Do Hee Gonzalez, Sandra Rodriguez, Ana Gallego-Delgado, Julio Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria |
title | Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria |
title_full | Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria |
title_fullStr | Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria |
title_full_unstemmed | Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria |
title_short | Treatment Reducing Endothelial Activation Protects against Experimental Cerebral Malaria |
title_sort | treatment reducing endothelial activation protects against experimental cerebral malaria |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229727/ https://www.ncbi.nlm.nih.gov/pubmed/35745497 http://dx.doi.org/10.3390/pathogens11060643 |
work_keys_str_mv | AT motasabrina treatmentreducingendothelialactivationprotectsagainstexperimentalcerebralmalaria AT bensaleljohanna treatmentreducingendothelialactivationprotectsagainstexperimentalcerebralmalaria AT parkdohee treatmentreducingendothelialactivationprotectsagainstexperimentalcerebralmalaria AT gonzalezsandra treatmentreducingendothelialactivationprotectsagainstexperimentalcerebralmalaria AT rodriguezana treatmentreducingendothelialactivationprotectsagainstexperimentalcerebralmalaria AT gallegodelgadojulio treatmentreducingendothelialactivationprotectsagainstexperimentalcerebralmalaria |